13 terminated. 13 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Terminated 13 |
| Phase 3 | 2 | Terminated 2 |
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis | Phase 2 | Terminated | InflaRx GmbH | 73 | 2025-01-02 | 2026-02-03 |
| A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) Brensocatib, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Insmed Incorporated | 214 | 2024-12-16 | 2026-06-29 |
| A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab Spesolimab, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 39 | 2024-05-08 | 2026-06-17 |
| Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). Deucravacitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 7 | 2023-11-30 | 2026-05-29 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa SAR444656 (KT-474), Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Sanofi | 70 | 2023-09-29 | 2025-12-11 |
| Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment Ruxolitinib 1.5% Cream - Hidradenitis Suppurativa | Phase 2 | Terminated | Milton S. Hershey Medical Center | 6 | 2022-10-13 | 2026-04-28 |
| A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) RIST4721, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Aristea Therapeutics, Inc. | 25 | 2022-07-18 | 2023-06-13 |
| A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa Bermekimab, Adalimumab, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Janssen Research & Development, LLC | 151 | 2021-10-12 | 2023-11-13 |
| Antibiotic Irrigations for Intra-Abdominal Drains Gentamicin Sulfate Inj 20mg/2ml vial for injection, Clindamycin phosphate 6 mg/1ml for injection, Placebo - Abdominal Abscess | Phase 2 | Terminated | University of Iowa | 2 | 2019-04-01 | 2026-09-03 |
| Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa MEDI8968, Saline - Hidradenitis Suppurativa | Phase 2 | Terminated | AstraZeneca | 224 | 2013-05-01 | 2016-09-01 |
| GSK2251052 in the Treatment of Complicated Intra-abdominal Infections Drug: GSK2251052, Meropenem, Placebo - Infections, Intestinal | Phase 2 | Terminated | GlaxoSmithKline | 15 | 2011-10-03 | 2017-11-29 |
| A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS drospirenone and ethinyl estradiol (YAZ), Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Massachusetts General Hospital | 4 | 2008-10-01 | 2014-02-10 |
| Safety and Effectiveness of tPA in Intra-abdominal Abscesses Tissue Plasminogen Activator, Normal Saline - Abscess | Phase 2 / Phase 3 | Terminated | University Health Network, Toronto | 35 | 2005-07-01 | 2014-01-14 |
Hidradenitis Suppurativa (10) · Abscess (2) · Abdominal Abscess (1) · Chronic Urticaria (1) · Hidradenitis (1) · Infections (1) · Intraabdominal Infections (1) · Peritonitis (1)
Infections (12) · Bacterial Infections (10) · Bacterial Infections and Mycoses (10) · Skin Diseases (10) · Skin Diseases, Bacterial (10) · Skin Diseases, Infectious (10) · Skin and Connective Tissue Diseases (10) · Sweat Gland Diseases (10) · Hidradenitis (9) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Inflammation (2) · Abscess (1) · Chronic Disease (1)
3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (1) · Adalimumab (1) · Ethinyl Estradiol (1) · Injections (1) · Meropenem (1) · Saline Solution (1) · Sodium Chloride (1) · Therapeutics (1) · Tissue Plasminogen Activator (1) · bermekimab (1) · brensocatib (1) · clindamycin phosphate (1) · deucravacitinib (1) · drospirenone (1) · drospirenone and ethinyl estradiol combination (1)
Aristea Therapeutics, Inc. (1) · AstraZeneca (1) · Beth Israel Deaconess Medical Center (1) · Boehringer Ingelheim (1) · GlaxoSmithKline (1) · InflaRx GmbH (1) · Insmed Incorporated (1) · Janssen Research & Development, LLC (1) · Massachusetts General Hospital (1) · Milton S. Hershey Medical Center (1) · Sanofi (1) · University Health Network, Toronto (1) · University of Iowa (1)
United States (12) · Canada (7) · Germany (5) · Poland (5) · Spain (5) · Australia (3) · Bulgaria (3) · France (3) · Greece (3) · Japan (2) · Netherlands (2) · South Korea (2) · Argentina (1) · Chile (1) · Czechia (1)
Alexandra B Kimball, MD, MPH (1) · Alexandra Kimball, MD, MPH (1) · Dheeraj Rajan, MD (1) · Murray Asch, MD (1) · Robert AK Lee, MD (1) · Scott Sherman, MD (1)
2023 (2)